Jeffrey  Dierks net worth and biography

Jeffrey Dierks Biography and Net Worth

Mr. Dierks is Chief Commercial Officer for Harmony Biosciences. Previously at Teva Pharmaceuticals, he held various leadership positions in Marketing, including Senior Director of US Pain Care, Sleep Disorders and Migraine Marketing. Prior to joining Teva, he held roles of increasing responsibility at several major pharmaceutical companies, including Janssen, Endo and Wyeth. Mr. Dierks has over 20 years of commercial experience, including several major product launches. He has led brand teams across numerous therapeutic areas, including CNS, Sleep Disorders, Pain Care and Migraine, as well as rare diseases.

He holds a bachelor’s degree from McDaniel College and a Master of Business Administration in marketing from the Temple Fox School of Business.

What is Jeffrey Dierks' net worth?

The estimated net worth of Jeffrey Dierks is at least $351,300.00 as of September 7th, 2021. Mr. Dierks owns 10,000 shares of Harmony Biosciences stock worth more than $351,300 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Dierks may own. Learn More about Jeffrey Dierks' net worth.

How do I contact Jeffrey Dierks?

The corporate mailing address for Mr. Dierks and other Harmony Biosciences executives is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. Harmony Biosciences can also be reached via phone at 484-539-9800 and via email at [email protected]. Learn More on Jeffrey Dierks' contact information.

Has Jeffrey Dierks been buying or selling shares of Harmony Biosciences?

During the past quarter, Jeffrey Dierks has sold $869,943.12 in Harmony Biosciences stock. Most recently, Jeffrey Dierks sold 21,496 shares of the business's stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a transaction totalling $869,943.12. Learn More on Jeffrey Dierks' trading history.

Who are Harmony Biosciences' active insiders?

Harmony Biosciences' insider roster includes Jeffrey Dayno (Insider), Jeffrey Dierks (Insider), John Jacobs (CEO), and Andreas Wicki (Director). Learn More on Harmony Biosciences' active insiders.

Are insiders buying or selling shares of Harmony Biosciences?

In the last year, insiders at the sold shares 4 times. They sold a total of 33,869 shares worth more than $1,267,489.12. The most recent insider tranaction occured on October, 29th when insider Jeffrey Dierks sold 21,496 shares worth more than $869,943.12. Insiders at Harmony Biosciences own 30.8% of the company. Learn More about insider trades at Harmony Biosciences.

Information on this page was last updated on 10/29/2024.

Jeffrey Dierks Insider Trading History at Harmony Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/29/2024Sell21,496$40.47$869,943.12View SEC Filing Icon  
9/27/2024Sell200$40.05$8,010.00View SEC Filing Icon  
3/15/2024Sell11,979$32.00$383,328.00View SEC Filing Icon  
3/8/2024Sell194$32.00$6,208.00View SEC Filing Icon  
10/3/2022Sell12,173$44.68$543,889.64View SEC Filing Icon  
8/22/2022Sell28,971$47.00$1,361,637.00View SEC Filing Icon  
4/1/2022Sell14,471$49.63$718,195.73View SEC Filing Icon  
11/1/2021Sell10,000$41.67$416,700.00View SEC Filing Icon  
9/7/2021Sell5,000$37.00$185,000.0010,000View SEC Filing Icon  
6/15/2021Sell15,000$31.32$469,800.0015,000View SEC Filing Icon  
See Full Table

Jeffrey Dierks Buying and Selling Activity at Harmony Biosciences

This chart shows Jeffrey Dierks's buying and selling at Harmony Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Harmony Biosciences Company Overview

Harmony Biosciences logo
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $35.16
Low: $34.57
High: $35.41

50 Day Range

MA: $35.09
Low: $32.13
High: $41.49

2 Week Range

Now: $35.16
Low: $28.14
High: $41.61

Volume

65,286 shs

Average Volume

474,836 shs

Market Capitalization

$2.01 billion

P/E Ratio

16.66

Dividend Yield

N/A

Beta

0.79